Research Field Drug discovery

Chiral Quest

Your left and right hands are chiral objects – they are mirror images but cannot be directly superimposed over each other. Many chemical reactions create both chiral forms (enantiomers) of a molecule, something that has proved problematic when synthesizing new drugs, as the two forms may have quite different properties. In the case of thalidomide, one enantiomer acts as a sedative and anti-emetic, while its mirror image causes nerve damage and severe birth defects.

As a result, most modern drugs contain only a single enantiomer, but with few chemical reactions available that guarantee success, it is no easy task. Now, a team from The Scripps Research Institute (TSRI) have engineered a more effective way of producing a single chiral form of a molecule (1).

“Drug discovery has seen a shift of interest towards three dimensional chiral molecules due to the potential to explore new chemical space in molecular recognition in biological systems,” says Jin-Quan Yu, lead researcher, and Frank and Bertha Hupp Professor of Chemistry at The Scripps Research Institute.

Yu’s lab engineer asymmetry into a potential drug molecule by directing a palladium catalyst to selectively break carbon–hydrogen bonds, and replace the hydrogen molecule with a variety of aryl groups, commonly used in drug development. Previously, this has been achieved by the process of conjugate addition, which requires an additional step of creating a double bond at the carbon. The new technique is easier, more precise, and reliably produced only the desired chiral form.

“This reaction constructs a beta-chiral center, which is a cornerstone in the synthesis of chiral molecules,” says Yu. The team have successfully tested the reaction with aliphatic amides and free carboxylic acids – common starting compounds for drug synthesis – and hope to expand the technique further. TSRI partner Bristol Myers-Squibb is already applying the new reaction to make a chiral amino acid needed to produce a candidate drug.

Receive content, products, events as well as relevant industry updates from The Translational Scientist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. G Chen et al., “Ligand-accelerated enantioselective methylene C(sp3)–H bond activation”, Science, 353, 1023-1027 (2016).
About the Author
William Aryitey

My fascination with science, gaming, and writing led to my studying biology at university, while simultaneously working as an online games journalist. After university, I travelled across Europe, working on a novel and developing a game, before finding my way to Texere. As Associate Editor, I’m evolving my loves of science and writing, while continuing to pursue my passion for gaming and creative writing in a personal capacity.

Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register